Design Therapeutics Reaches Analyst Target Price
May 08, 2024 at 07:17 AM EDT
In recent trading, shares of Design Therapeutics Inc (DSGN) have crossed above the average analyst 12-month target price of $4.67, changing hands for $4.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..